Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB87755
CAS No: 849217-68-1
Chemical Name: N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
Warning: Last items in stock!
Availability date:
Molecular Formula | C28H24FN3O5 |
Molecular Weight | 501.5 |
CAS Numbers | 849217-68-1 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMF: 3 mg/ml DMSO: 5 mg/ml DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml Ethanol: 2 mg/ml |
Purity | 98% by HPLC |
Synonym | BMS-907351; BMS907351; Cabozantinib; XL184; XL-184 |
IUPAC/Chemical Name | N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
InChl Key | ONIQOQHATWINJY-UHFFFAOYSA-N |
InChl Code | InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34) |
SMILES Code | COC1=C(OC)C=C(C(OC2=CC=C(NC(C3(C(NC4=CC=C(F)C=C4)=O)CC3)=O)C=C2)=CC=N5)C5=C1 |
References | 1) Yakes, F.M., Chen, J., Tan, J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10(12), 2298-2308 (2011). 2) Rausch, K., Hackett, B., Weinbren, N.R., S., et al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus. Cell Rep. 18(3), 804-815 (2017). |
A pan tyrosine kinase inhibitor that primarily targets VEGFR2 (IC50 = 0.035 nM) and c-Met (IC50 = 1.3 nM) but also inhibits RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively).